All News

AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

Ref: Business Wire

Tags: Press Release AVEO Leukaemias Clinical Research (R&D)ficlatuzumab cytarabine

ADVANZ PHARMA Corp. Limited Completes Voluntarily Delisting from the Toronto Stock Exchange

Ref: CNW

Tags: Press Release ADVANZ PHARMA Corporate Affairs

HaloVax Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection

Ref: PR Newswire

Tags: Press Release HaloVax Hoth Therapeutics Voltron COVID-19 Immunisation Corporate Affairs Licensing

Chan Zuckerberg Initiative Commits $25 Million to Speed Development of COVID-19 Treatments

Ref: PR Newswire

Tags: Press Release COVID-19 Corporate Affairs

How to boost immune response to vaccines in older people

Ref: Babraham Institute

Tags: Press Release Immunisation Clinical Research (R&D)imiquimod

BERGENBIO PROVIDES COVID-19 IMPACT ASSESSMENT

Ref: BerGenBio

Tags: Press Release BerGenBio Corporate Affairs

SMC response to COVID-19

Ref: SMC

Tags: Press Release Scottish Medicines Consortium Regulatory Affairs

PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

Ref: GlobeNewswire

Tags: Press Release PDS Biotechnology Corporate Affairs

Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment

Ref: Business Wire

Tags: Press Release Sun Pharmaceutical COVID-19 Marketing & Sales hydroxychloroquine

Failed studies prompt Lundbeck to terminate foliglurax in Parkinson's disease, Lu AG06466 in Tourette syndrome

Ref: Lundbeck, Cision

Tags: Top Story Lundbeck Parkinson's Clinical Research (R&D)Foliglurax Lu AG06466